FOSCO Study (Functional Outcomes Study of OROS (Osmotic-controlled Release Oral Delivery System) Methylphenidate

2014-07-24 14:10:56 | BioPortfolio


The primary objective of this study is to evaluate the effectiveness at 12 weeks of the OROS Methylphenidate for children with Attention Deficit Hyperactivity Disorder (ADHD). The treatment effectiveness will be evaluated based upon the response and remission rate which are evaluated using the K-ARS (Korean ADHD Rating Scale) and CGI (Clinical Global Impression). The secondary objectives of this study are to assess changes in overall functioning in activities of daily living and social functioning and to examine the impact of symptomatic remission on functional changes and a casual relationship between remission and functional changes after administering OROS Methylphenidate in children and adolescents with ADHD.


This is an open label (all people involved know the identity of the intervention), single arm, multicenter, prospective study evaluating the effectiveness of OROS (Osmotic-controlled Release Oral delivery System) methylphenidate for 12 weeks in treating children with Attention Deficit Hyperactivity Disorder (ADHD). Recently, the final aim of the treatment of ADHD goes beyond the stage of simple response to a drug and is being narrowed down to improvement in quality of life (QOL), day living (home and school life), functional recovery and the improvement of social relationships. Treatment effectiveness will be evaluated based upon response and remission rate. The secondary objectives are to examine how treatment with OROS Methylphenidate affects overall function and to determine the impact symptomatic remission has on changes in overall function. Adverse events will be reported during the study period. From the time point of starting the first procedure related to the study until the completion of all the study procedures, the investigator will follow up on any ongoing clinically significant abnormal results until stabilized or resolved. The study will assess safety and tolerability using the Symptom Rating Scale at every visit, clinical laboratory tests at visit 1, ECG at visit 1, vital signs/height/weight at first and last visit and physical exam at visit 1. The drug effect will be assessed by evaluating the improvement of subjects' ADHD symptoms before and after the treatment using the following standardized assessment surveys: Child Health and Illness Profile (CHIP), Korean ADHD Rating Scale (K-ARS), Clinical Global Impression of Severity (CGI-S) scale, Clinical Global Impression of Improvement (CGI-I) scale, Beck Depression Inventory (BDI), Parenting Stress Index (PSI), Comprehensive Attention Test (CAT) measures and academic performance. The patients will be on once daily study medication starting at 18 mg/day in children with less than 30 kg of body weight or at 27 mg/day in children with more than 30 kg. The dose is increased approximately every 7 days in 9 mg or 18 mg increments to 54 mg/day based on the clinical judgment of the investigator

Study Design

Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment


Attention Deficit Disorder With Hyperactivity


OROS methylphenidate hydrochloride




Janssen Korea, Ltd., Korea

Results (where available)

View Results


Published on BioPortfolio: 2014-07-24T14:10:56-0400

Clinical Trials [1944 Associated Clinical Trials listed on BioPortfolio]

CONCERTA® (OROS® Methylphenidate Hydrochloride) for the Treatment of Attention Deficit Hyperactivity Disorder in Adults

The purpose of this pilot study is to evaluate the safety, tolerability and potential effectiveness of CONCERTA® (methylphenidate hydrochloride extended-release tablets), a central nervou...

A Multicenter Study Comparing the Efficacy and Safety of OROS® Methylphenidate HCl, Ritalin® (Methylphenidate HCl) and Placebo in Children With Attention Deficit Hyperactivity Disorder

The purpose of this study is to evaluate the efficacy and safety of OROS® Methylphenidate HCl as compared with placebo and standard immediate-release Ritalin® (taken three time per day) ...

Genetic Polymorphism and OROS-Methylphenidate Treatment in Attention Deficit Hyperactivity Disorder(ADHD)

The purpose of this study is to examine whether genetic polymorphisms in drug transporters were associated with the side effects of OROS-methylphenidate medication in attention deficit/hyp...

A Study to Determine Effective and Tolerable Titration Scheme for OROS-Methylphenidate in Children With Attention-deficit Hyperactivity Disorder

The purpose of the study is to investigate the clinical benefit of switching children with ADHD from immediate-release methylphenidate (IR-MPH) to OROS-methylphenidate under the correct do...

Study of the Effects of OROS Methylphenidate (Concerta) on Attention and Memory

This study investigates whether OROS-methylphenidate improves performance on different aspects of attention and memory in children with Attention-Deficit Hyperactivity Disorder.

PubMed Articles [8417 Associated PubMed Articles listed on BioPortfolio]

Effects of Long-Term Use of Prescription Methylphenidate on Myocardial Performance in Children with Attention-Deficit/Hyperactivity Disorder: A Tissue Doppler Imaging Study.

Many children diagnosed with attention-deficit/hyperactivity disorder are treated with methylphenidate (MPH). The purpose of this study was to evaluate the relationship between long-term use of osmoti...

Neurocognitive effects of methylphenidate in adults with attention-deficit/hyperactivity disorder: A meta-analysis.

PIEVSKY, M. A., and R. E. McGrath. Neurocognitive effects of methylphenidate in adults with attention-deficit/hyperactivity disorder: A meta-analysis…NEUROSCI BIOBEHAV REV 81(1) XXX-XXX, 2017.- This...

The effectiveness of methylphenidate in the management of Attention Deficit Hyperactivity Disorder (ADHD) in people with intellectual disabilities: A systematic review.

The effectiveness of psychostimulants, primarily methylphenidate (MPH), in the treatment of Attention Deficit Hyperactivity Disorder (ADHD) in the general population of typically growing children and ...

The Jury Is Still Out on the Benefits and Harms of Methylphenidate for Children and Adolescents With Attention-Deficit/Hyperactivity Disorder.

Much remains unclear about the benefits and harms of methylphenidate for children and adolescents with attention-deficit/hyperactivity disorder (ADHD). Between 2012 and 2018, we conducted two Cochrane...

Aripiprazole/Methylphenidate Combination in Children and Adolescents with Disruptive Mood Dysregulation Disorder and Attention-Deficit/Hyperactivity Disorder: An Open-Label Study.

Disruptive mood dysregulation disorder (DMDD) is characterized by nonepisodic irritability and has a high rate of comorbidity with attention-deficit/hyperactivity disorder (ADHD). This is the first st...

Medical and Biotech [MESH] Definitions


A propylamine derivative and selective ADRENERGIC UPTAKE INHIBITOR that is used in the treatment of ATTENTION DEFICIT HYPERACTIVITY DISORDER.

A behavior disorder originating in childhood in which the essential features are signs of developmentally inappropriate inattention, impulsivity, and hyperactivity. Although most individuals have symptoms of both inattention and hyperactivity-impulsivity, one or the other pattern may be predominant. The disorder is more frequent in males than females. Onset is in childhood. Symptoms often attenuate during late adolescence although a minority experience the full complement of symptoms into mid-adulthood. (From DSM-IV)

A dextroamphetamine drug precursor that also functions as a CENTRAL NERVOUS SYSTEM STIMULANT and DOPAMINE UPTAKE INHIBITOR and is used in the treatment of ATTENTION DEFICIT HYPERACTIVITY DISORDER.

A central nervous system stimulant used most commonly in the treatment of attention-deficit disorders in children and for narcolepsy. Its mechanisms appear to be similar to those of DEXTROAMPHETAMINE.

More From BioPortfolio on "FOSCO Study (Functional Outcomes Study of OROS (Osmotic-controlled Release Oral Delivery System) Methylphenidate"

Quick Search


Relevant Topics

Pediatrics is the general medicine of childhood. Because of the developmental processes (psychological and physical) of childhood, the involvement of parents, and the social management of conditions at home and at school, pediatrics is a specialty. With ...

Attention deficit hyperactivity disorder (ADHD)
Attention deficit hyperactivity disorder (ADHD) is a group of behavioural symptoms that include inattentiveness, hyperactivity and impulsiveness. Attention deficit disorder (ADD) is a sub-type of ADHD - symptoms of ADHD include: a short attenti...

Searches Linking to this Trial